Business Context and Reporting Period
This Form 8-K filing by Callan JMB Inc. (CJMB) covers events occurring between February 4, 2025, and February 7, 2025. The primary event is the completion of the Company's Initial Public Offering (IPO) on The Nasdaq Capital Market. The filing details the entry into a material definitive underwriting agreement, the closing of the offering, the partial exercise of an over-allotment option, and the appointment of three new independent directors.
Key Financial Metrics and Capital Structure
- Offering Price: $4.00 per share.
- Shares Sold (Initial): 1,280,000 shares.
- Shares Sold (Over-Allotment): 163,569 shares.
- Total Shares Sold: 1,443,569 shares.
- Net Proceeds (Initial): Approximately $4.1 million (after underwriting discounts and expenses).
- Net Proceeds (Over-Allotment): Approximately $592,000 (prior to deducting discounts and expenses).
- Underwriting Discount: 8.5% of gross proceeds.
- Expense Fee: 1.0% of gross proceeds.
- Representative's Warrants: Issued to purchase 64,000 shares (initial) and 8,179 shares (over-allotment) at an exercise price of $4.80 per share (120% of offering price).
Material Changes and Corporate Actions
The Company transitioned from a private entity to a public company listed on The Nasdaq Capital Market under the symbol "CJMB" on February 5, 2025. The offering closed on February 6, 2025, with the partial over-allotment closing on February 7, 2025. Additionally, the Board of Directors was expanded with the appointment of Liberty Duke, Mark Meller, and Gerald Dial, all of whom are independent and have been assigned to the Audit, Compensation, and Nominating and Corporate Governance committees.
Guidance, Outlook, and Risks
Use of Proceeds: The Company intends to use net proceeds primarily for sales support, marketing expenses, customer expansion, and general corporate purposes, including working capital.
Lock-Up Agreement: The Company, its officers, and directors have agreed not to sell or dispose of any shares of Common Stock or convertible securities until February 4, 2026, without the prior written consent of the Representative.
Risks and Contingencies: The filing notes that the Underwriting Agreement contains customary representations and warranties but explicitly states these are not for the benefit of investors. Investors are directed to other Commission filings for factual information regarding the Company's current state of affairs.
Investor Verification Checklist
- Verify the final total net proceeds after all underwriting discounts and offering expenses are deducted from the over-allotment portion.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) and Representative's Warrant (Exhibit 4.1) for specific terms and conditions.
- Confirm the exact composition of the Board of Directors and the specific responsibilities of the newly appointed committee chairs.
- Monitor the Company's subsequent filings for the detailed breakdown of how the raised capital is allocated against the stated use of proceeds.
- Check the expiration date and exercise terms of the Representative's Warrants (August 6, 2025, to February 6, 2030).